Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of the Safety and Efficacy of ALX-101 Topical Gel Administered Twice Daily in Adult and Adolescent Subjects With Moderate Atopic Dermatitis

NCT03175354 is registered in ClinicalTrials.gov with Ralexar Therapeutics, Inc. as lead sponsor.

NCT NCT03175354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03175354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of the Safety and Efficacy of ALX-101 Topical Gel Administered Twice Daily in Adult and Adolescent Subjects With Moderate Atopic Dermatitis
Lead sponsor
Ralexar Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 26, 2017
Completion date
June 29, 2018
Enrollment
209 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, eczema, atopic